Targeted therapy vs. DNA-adduct formation-guided design: thoughts about the future of metal-based anticancer drugs
出版年份 2012 全文链接
标题
Targeted therapy vs. DNA-adduct formation-guided design: thoughts about the future of metal-based anticancer drugs
作者
关键词
-
出版物
DALTON TRANSACTIONS
Volume 41, Issue 27, Pages 8226
出版商
Royal Society of Chemistry (RSC)
发表日期
2012-05-01
DOI
10.1039/c2dt30075c
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A Better Platinum-Based Anticancer Drug Yet to Come?
- (2012) Ulrike Olszewski et al. Anti-Cancer Agents in Medicinal Chemistry
- Catalytic metallodrugs targeting HCV IRES RNA
- (2012) Seth Bradford et al. CHEMICAL COMMUNICATIONS
- Zinc(ii) complexes of constrained antiviral macrocycles
- (2012) Allison Ross et al. DALTON TRANSACTIONS
- Cancer genetics: Evolution after tumour spread
- (2012) Steven C. Clifford NATURE
- Clonal selection drives genetic divergence of metastatic medulloblastoma
- (2012) Xiaochong Wu et al. NATURE
- From Conventional to Unusual Enzyme Inhibitor Scaffolds: The Quest for Target Specificity
- (2011) Eric Meggers ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Molecular Predictors of Response to Antiangiogenesis Therapies
- (2011) Armin Gerger et al. CANCER JOURNAL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- How do real tumors become resistant to cisplatin?
- (2011) Piet Borst et al. CELL CYCLE
- Approaching tumour therapy beyond platinum drugs
- (2011) A. Bergamo et al. JOURNAL OF INORGANIC BIOCHEMISTRY
- Metal-Based Inhibition of Poly(ADP-ribose) Polymerase − The Guardian Angel of DNA
- (2011) Filipa Mendes et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structurally Sophisticated Octahedral Metal Complexes as Highly Selective Protein Kinase Inhibitors
- (2011) Li Feng et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling
- (2011) W van Veelen et al. ONCOGENE
- Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin
- (2010) Chi-Hui Tang et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death
- (2010) L. Galluzzi et al. CANCER RESEARCH
- Downregulation of Bcl-x L and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy
- (2010) Emilie Varin et al. CARCINOGENESIS
- Novel Metals and Metal Complexes as Platforms for Cancer Therapy
- (2010) Michael Frezza et al. CURRENT PHARMACEUTICAL DESIGN
- Metal-based drugs for malaria, trypanosomiasis and leishmaniasis: recent achievements and perspectives
- (2010) Maribel Navarro et al. DRUG DISCOVERY TODAY
- Cancer stemness and metastasis: Therapeutic consequences and perspectives
- (2010) Joana Monteiro et al. EUROPEAN JOURNAL OF CANCER
- HER2 as a target for breast cancer therapy
- (2010) Elda Tagliabue et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Towards global consensus in the treatment of gastrointestinal stromal tumor
- (2010) Peter Reichardt et al. Expert Review of Anticancer Therapy
- Recent advances in the discovery of small molecule mTOR inhibitors
- (2010) Abhijit Roychowdhury et al. Future Medicinal Chemistry
- An Iron-Based Cytosolic Catalase and Superoxide Dismutase Mimic Complex
- (2010) Adolfo Horn et al. INORGANIC CHEMISTRY
- TP53Mutations and Pathologic Complete Response to Neoadjuvant Cisplatin and Fluorouracil Chemotherapy in Resected Oral Cavity Squamous Cell Carcinoma
- (2010) Federica Perrone et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
- (2010) Daniel P. Silver et al. JOURNAL OF CLINICAL ONCOLOGY
- KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- The new platinum(IV) derivative LA-12 shows stronger inhibitory effect on Hsp90 function compared to cisplatin
- (2010) Veronika Kvardova et al. Molecular Cancer
- Hsp90: A Drug Target?
- (2010) Jeffrey M. Holzbeierlein et al. Current Oncology Reports
- Targeted Cancer Therapeutics
- (2009) William N. Hait CANCER RESEARCH
- Metal Complexes, their Cellular Targets and Potential for Cancer Therapy
- (2009) Di Chen et al. CURRENT PHARMACEUTICAL DESIGN
- Cisplatin Versus Carboplatin in NSCLC: Is There One “Best” Answer?
- (2009) Rachel E. Sanborn CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Non-traditional platinum compounds for improved accumulation, oral bioavailability, and tumor targeting
- (2009) Katherine S. Lovejoy et al. DALTON TRANSACTIONS
- Satraplatin for the therapy of castration-resistant prostate cancer
- (2009) Guru Sonpavde et al. Future Oncology
- Gene signatures of pulmonary metastases of renal cell carcinoma reflect the disease-free interval and the number of metastases per patient
- (2009) Daniela Wuttig et al. INTERNATIONAL JOURNAL OF CANCER
- In vivo tumour and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model
- (2009) A. Bergamo et al. JOURNAL OF INORGANIC BIOCHEMISTRY
- Inhibition of transcription by platinum antitumor compounds
- (2009) Ryan C. Todd et al. Metallomics
- Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells
- (2009) K. Simonin et al. MOLECULAR CANCER THERAPEUTICS
- Mechanisms of Hedgehog pathway activation in cancer and implications for therapy
- (2009) Suzie J. Scales et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- KP1019, A New Redox-Active Anticancer Agent - Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients
- (2008) Christian G. Hartinger et al. CHEMISTRY & BIODIVERSITY
- New pharmacological strategies against metastatic spread
- (2008) G.Y. Perret et al. FUNDAMENTAL & CLINICAL PHARMACOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started